依维莫司洗脱生物可吸收冠状动脉支架3年临床结局:ABSORB III试验
ABSORB III试验将2008例冠心病患者随机分配至Absorb依维莫司洗脱生物可吸收血管支架(BVS)或钴铬依维莫司洗脱支架(EES),随访3年。3年靶病变失败率BVS组13.4%对EES组10.4%(p=0.06),1至3年间分别为7.0%和6.0%(p=0.39);BVS组靶血管心肌梗死(8.6%对5.9%,p=0.03)和器械血栓(2.3%对0.7%,p=0.01)显著增高。
要点
- BVS组3年靶血管心肌梗死和器械血栓发生率显著高于EES组,靶病变失败率组间差异无统计学意义。
- 1至3年间靶病变失败率BVS组7.0%对EES组6.0%(p=0.39),差异无统计学意义。
- 参考血管直径<2.25 mm的极细小血管置入BVS是3年TLF和支架血栓的独立预测因素。
核心结论
- ABSORB III试验3年随访显示BVS组不良事件率高于EES组,尤其是靶血管心肌梗死和器械血栓。
- 需更长期临床随访以确定聚合物支架生物吸收是否影响患者预后。
研究设计与样本
- ABSORB III为随机对照试验(RCT),纳入2008例冠心病患者,随机分配至BVS或钴铬EES。
- 按随机治疗分组分析3年累积及1至3年间的临床结局。
主要发现
- 3年靶病变失败(心源性死亡、靶血管心肌梗死或缺血驱动的靶病变血运重建)BVS组13.4%对EES组10.4%(p=0.06)。
- 1至3年间靶病变失败BVS组7.0%对EES组6.0%(p=0.39)。
- 3年靶血管心肌梗死BVS组8.6%对EES组5.9%(p=0.03)。
- 3年器械血栓BVS组2.3%对EES组0.7%(p=0.01)。
- 在BVS组中,治疗参考血管直径<2.25 mm的极细小血管是3年TLF和支架血栓的独立预测因素。
临床怎么用
- 对于参考血管直径<2.25 mm的极细小血管病变,置入BVS需谨慎,因其与3年TLF和支架血栓独立相关。
- BVS置入后应关注靶血管心肌梗死和器械血栓风险,尤其在3年随访期内。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Absorb everolimus-eluting poly-L-lactic acid-based bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support functions similar to metallic drug-eluting stents (DES), followed by complete bioresorption in approximately 3 years with recovery of vascular structure and function. The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI], or ischemia-driven target lesion revascularization) at 1 year in 2,008 patients with coronary artery disease randomized to BVS versus cobalt-chromium everolimus-eluting stents (EES). OBJECTIVES: This study sought to assess clinical outcomes through 3 years following BVS implantation. METHODS: Clinical outcomes from the ABSORB III trial were analyzed by randomized treatment assignment cumulative through 3 years, and between 1 and 3 years. RESULTS: The primary composite endpoint of target lesion failure through 3 years occurred in 13.4% of BVS patients and 10.4% of EES patients (p = 0.06), and between 1 and 3 years in 7.0% versus 6.0% of patients, respectively (p = 0.39). TVMI through 3 years was increased with BVS (8.6% vs. 5.9%; p = 0.03), as was device thrombosis (2.3% vs. 0.7%; p = 0.01). In BVS-assigned patients, treatment of very small vessels (those with quantitatively determined reference vessel diameter <2.25 mm) was an independent predictor of 3-year TLF and scaffold thrombosis. CONCLUSIONS: In the ABSORB III trial, 3-year adverse event rates were higher with BVS than EES, particularly TVMI and device thrombosis. Longer-term clinical follow-up is required to determine whether bioresorption of the polymeric scaffold will influence patient prognosis. (ABSORB III Randomized Controlled Trial [RCT] [ABSORB-III]; NCT01751906).
引用
- Kereiakes DJ, Ellis SG, Metzger C, et al. 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. J Am Coll Cardiol. 2017. PMID: 29100702. doi:10.1016/j.jacc.2017.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。